Autonomic Regulation Therapy To Improve Symptoms And Clinical Outcomes In Patients With Heart Failure And Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study Results
Marvin Konstam,James Udelson,Douglas Mann,Javed Butler,Jeffrey Ardell,Gaetano M. De Ferrari,Helmut Klein,Gerasimos Filippatos,Marco Metra,Inder Anand,Nicole Close,Ben Saville,Bruce KenKnight,Lorenzo DiCarlo,Scott Mindrebo,Perry Rice,John Parker,John Teerlink
DOI: https://doi.org/10.1016/j.cardfail.2023.10.468
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Introduction For patients with HFrEF, persistent HF symptoms while receiving Guideline Directed Medical Therapy (GDMT) augurs a worse prognosis. Hypothesis Based on symptom and function improvements observed in a feasibility study, autonomic regulation therapy (ART) using vagal nerve stimulation (VNS) may provide incremental clinical benefit. Methods This randomized, controlled, open-label pivotal study was designed to evaluate the long-term outcome of CV death (CVD) or hospitalization for HF (HFH) as a primary endpoint, and included an embedded study of 6-9 month changes in LVEF, 6-minute walk distance (6MWD), and Kansas City Cardiomyopathy Questionnaire (KCCQ). Randomization of up to 1,000 patients was planned in North America and Europe. (https://clinicaltrials.gov/ct2/show/NCT03425422). Entry required use of GDMT, persistent symptoms (NYHA 2 with HFH during prior 12 months or NYHA 3), LVEF &le 35%, NTproBNP &ge 800 pg/ mL, and 6MWD limited to 150- 450 m. Interim analyses were used to assess for futility, to evaluate symptom and function endpoints, and to analyze probabilities of reducing CVD/HFH for adaptive sample size decisions. During the COVID pandemic, the statistical analysis plan was amended to add pre-COVID vs. COVID populations to the prespecified list of subgroup analyses. Results There were 533 patients who continued GDMT and were randomized 2:1 to right cervical VNS or no additional intervention with median age 65 years, 84% males, median LVEF 26%, median NT-proBNP 2,204 pg/ml, therapy with beta-blocker 96%, ACE/ARB/ARNI 85%, MRA 82%, SGLT2i 11%, and adjuvant CRT 22% and ICD 56%. The Data and Safety Monitoring Committee recommended study continuation after the second planned interim analysis. However, the sponsor terminated the study subsequently for reasons unrelated to futility, patient safety, or device malfunction. Executive Committee members and all personnel directly involved in the study remained blinded until the database (DB) lock. Because of reduced statistical power, an SAP amendment before DB lock detailed a pre-specified exploratory analysis of a hierarchical composite endpoint (CVD, HFH, and KCCQ) using a win ratio and Finkelstein Schoenfeld methodology, and added subgroups to the previously specified list to expand exploration of potential efficacy. Efficacy and safety results will be presented. Conclusions Despite premature termination, patients enrolled in the ANTHEM-HFrEF trial represent a robust population for exploring the efficacy and safety of ART for treating heart failure.
cardiac & cardiovascular systems